Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases. (15th March 2019)

• Record Type: Journal Article
• Authors: Zhang, Sudong; Zhang, Ping; Wang, Zhao; Liu, Li; He, Yi; Jiang, Erlie; Wei, Jialin; Yang, Donglin; Zhang, Rongli; Zhai, Weihua; Ma, Qiaoling; Pang, Aiming; Huang, Yong; Han, Mingzhe; Feng, Sizhou
• Is Part Of: Future microbiology. Volume 14:Number 6(2019)
• Page Start: 477
• Page End: 488
• Publication Date: 2019-03-15
• Subjects: allogeneic hematopoietic stem cell transplantation -- hematological diseases -- invasive fungal disease -- posaconazole -- salvage therapy; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb-2018-0344
• Languages: English
• ISSNs: 1746-0913

Abstract

Aim: Posaconazole (POS) is an extended-spectrum triazole approved for treatment of refractory invasive fungal disease. Outcome analysis of POS salvage therapy is of great clinical significance.Methods: We retrospectively reviewed data for 113 patients who received POS oral suspension as salvage therapy between December 2013 and May 2018.Results: Cumulative success rate at 12 weeks was 53.1% (60/113) with a rapid increase within the first 3–4 weeks and a plateau at 6 weeks after POS initiation. Multivariate logistic regression analysis showed that disseminated infection, prolonged neutropenia, severe graft-versus-host disease and high-dose steroid use were independent risk factors of response.Conclusion: POS oral suspension is effective as a salvage therapy for invasive fungal disease.